Kisspeptin-10

Kisspeptin-10 is a ten-amino-acid fragment of the kisspeptin family, the peptides encoded by the KISS1 gene. It sits above the reproductive hormone axis rather than inside it, acting on receptors carried by the neurons that release gonadotrophin-releasing hormone.

In healthy men, giving it intravenously produces an acute rise in luteinising hormone and, with continued administration, a rise in testosterone. That is the reliable human picture in full: a small number of short studies measuring an endocrine signal. It is worth separating from kisspeptin-54, a longer relative that carries most of the repeated-administration human data and behaves differently in living systems. Kisspeptin is also named on the WADA Prohibited List, which settles the practical question for any tested athlete before the evidence discussion begins.

Kisspeptin-10 is the shortest of the biologically active kisspeptin fragments. The KISS1 gene produces a longer precursor that is cleaved into several peptides sharing a common active end, of which kisspeptin-54 and kisspeptin-10 are the two most studied. They bind the same receptor.

They are not interchangeable, and the difference is not academic. Work in animals comparing the two directly found kisspeptin-54 the more potent of the pair in living systems, which is part of why repeated-administration human studies have generally used the longer peptide rather than the shorter one. When a claim about kisspeptin appears with no number attached to it, the first question worth asking is which peptide the underlying study actually gave.

Where the Biology Gets Interesting

Most hormone discussion in performance circles starts at the gonad or at the pituitary. Kisspeptin sits a step above both. Neurons expressing the KISS1R receptor sit upstream of the gonadotrophin-releasing hormone neurons that drive the pituitary, so kisspeptin signalling is the input that governs whether the axis pulses at all.

That position is why the compound draws interest, and it is also why it is difficult to reason about. An upstream regulator does not carry one downstream effect. It carries whatever effect the rest of the axis is currently capable of producing. Adding signal to a young healthy axis that is already signalling normally is a different proposition from adding it to one that has lost the signal, and the human work here was done exclusively in the first group.

The Mechanism, Without Overstating It

Kisspeptin binds KISS1R, a G-protein-coupled receptor expressed on gonadotrophin-releasing hormone neurons in the hypothalamus. Activation there increases release of gonadotrophin-releasing hormone, which reaches the anterior pituitary and drives secretion of luteinising hormone and, to a lesser degree, follicle-stimulating hormone. Luteinising hormone acting on testicular Leydig cells is what raises testosterone. Every step in that chain is indirect, and each one can fail independently of the others.

The current authoritative review of this system treats kisspeptin as the upstream regulator of reproductive function rather than as a hormone with effects of its own, and that framing is worth holding onto. The peptide does not act on muscle, on connective tissue, or on metabolic pathways directly. Its reach is limited to what a functioning hypothalamic-pituitary-gonadal axis does downstream of it.

The most common error on this compound is carrying kisspeptin-54 findings across to kisspeptin-10 without saying so. The two are routinely written about as one substance. They are not one substance, and the animal comparison described above found a real potency difference between them.

The second error is treating an acute endocrine response as a durable one. The human work here is measured in hours. Nothing in it addresses what sustained administration does to an axis whose defining feature is that it responds to pulsatile rather than constant input. That is an open question on this page, not a settled one, and none of the sources reviewed here can close it.

The third error is scope. A luteinising hormone response is a laboratory measurement. Fertility, libido, body composition, strength and training outcomes were not measured by any source cited on this page, and no amount of mechanistic plausibility substitutes for measuring them.

The only repeated-administration human safety data among these sources used kisspeptin-54 rather than kisspeptin-10, and it is small. Five healthy women received it on a repeated schedule through the follicular phase, monitored across two menstrual intervals against a saline comparison. Menstrual cyclicity persisted in all five, ovulation arrived roughly two days earlier than under saline, and the pituitary still responded acutely to both kisspeptin-54 and gonadotrophin-releasing hormone afterwards. That is reassuring as far as it goes, and it goes about as far as five participants and two monitored intervals allow.

No source here establishes a safety profile for kisspeptin-10 itself under repeated administration, in men, or over any period longer than a day. Material sold as kisspeptin-10 outside a research setting carries the usual identity and purity questions, and there is no approved product anywhere against which to compare it.

Anti-doping status is not a footnote on this compound. Kisspeptin and its agonist analogues are named on the WADA Prohibited List among testosterone-stimulating peptides in males, prohibited at all times both in and out of competition, and classed as a non-specified substance. Any athlete subject to testing should treat that as decisive on its own.

Read honestly, this entry supports one sentence: in healthy men, kisspeptin-10 given intravenously produces an acute rise in luteinising hormone and, with continued administration, in testosterone. Almost everything people want from that sentence lies outside it.

A testosterone rise measured over hours in a laboratory is not the same object as a sustained change in circulating testosterone, and neither of those is the same object as a change in strength, body composition, recovery or wellbeing. The chain running from the first to the last is long, and every link in it is unmeasured in the sources reviewed here. The defensible position is that kisspeptin-10 is an interesting upstream signal with a small acute human record and no outcome data at all.

Not the same peptide as kisspeptin-54. The two share a receptor and a common active end, but a direct animal comparison found kisspeptin-54 the more potent of the pair in living systems, and the repeated-administration human work used the longer peptide rather than this one.

Not a testosterone therapy. The human record is an acute luteinising hormone and testosterone response measured over hours in fewer than twenty healthy men, with nothing describing sustained levels or what follows when administration stops.

Not permitted in tested sport. Kisspeptin and its agonist analogues are named on the WADA Prohibited List among testosterone-stimulating peptides in males, prohibited at all times and classed as a non-specified substance.

Not evidence for fertility, libido or body composition. No source cited on this page measured any of the three, and an upstream endocrine signal is among the weakest available grounds for inferring them.

Not a protocol or personal-use guide. The human studies behind this entry were designed to probe how the hypothalamic axis behaves, not to test a treatment, and reading them as dosing guidance misreads what they set out to do.

Kisspeptin-10 is one of the more scientifically interesting compounds in this library and one of the least useful to act on. The biology is well characterised, the human work is real rather than borrowed from an adjacent molecule, and the gap between what was measured and what is claimed for it online is unusually wide.

Two facts settle the practical question ahead of any evidence discussion: kisspeptin is prohibited at all times in tested sport, and there is no human outcome data of any kind. This entry exists because the confusion between kisspeptin-10 and kisspeptin-54 is worth clearing up, not because there is something here to use.